1. Home
  2. ACM vs CORT Comparison

ACM vs CORT Comparison

Compare ACM & CORT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo AECOM

ACM

AECOM

HOLD

Current Price

$62.43

Market Cap

8.7B

ML Signal

HOLD

Logo Corcept Therapeutics Incorporated

CORT

Corcept Therapeutics Incorporated

HOLD

Current Price

$123.34

Market Cap

9.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ACM
CORT
Founded
1980
1998
Country
United States
United States
Employees
N/A
N/A
Industry
Military/Government/Technical
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
8.7B
9.7B
IPO Year
2007
2001

Fundamental Metrics

Financial Performance
Metric
ACM
CORT
Price
$62.43
$123.34
Analyst Decision
Strong Buy
Buy
Analyst Count
10
5
Target Price
$131.30
$96.50
AVG Volume (30 Days)
2.1M
1.1M
Earning Date
05-11-2026
04-30-2026
Dividend Yield
1.51%
N/A
EPS Growth
42.71
N/A
EPS
1.29
0.09
Revenue
$16,139,622,000.00
$761,407,000.00
Revenue This Year
N/A
$26.08
Revenue Next Year
$6.06
$26.98
P/E Ratio
$50.38
$1,369.33
Revenue Growth
0.21
12.79
52 Week Low
$60.35
$28.66
52 Week High
$135.52
$124.14

Technical Indicators

Market Signals
Indicator
ACM
CORT
Relative Strength Index (RSI) 42.69 73.80
Support Level $60.35 $76.41
Resistance Level $72.43 N/A
Average True Range (ATR) 2.39 3.54
MACD -0.33 0.38
Stochastic Oscillator 27.88 96.66

Price Performance

Historical Comparison
ACM
CORT

About ACM AECOM

Aecom is one of the largest global providers of advisory, design, and engineering services. It serves a broad spectrum of end markets, including water, transportation, and environment. Based in Dallas, Aecom employs 51,000 people. The company generated $16.1 billion in sales in fiscal 2025.

About CORT Corcept Therapeutics Incorporated

Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic, and neuropsychiatric disorders by modulating the effect of the cortisol hormone. The company markets Korlym (mifepristone) tablets and its authorized generic version, which is an oral medication for the treatment of hypercortisolism (also known as Cushing's syndrome). Additionally, its pipeline contains several key compounds, such as Relacorilant, Dazucorilant, Miricorilant, etc., that are being evaluated in clinical trials as potential treatments for a variety of serious disorders like hypercortisolism, solid tumors (including ovarian, endometrial, cervical, pancreatic, and prostate cancers), ALS, and MASH.

Share on Social Networks: